CA
LYEL icon

Clearstead Advisors’s Lyell Immunopharma LYEL Stock Holding History

Clearstead Advisors’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$280K Sell
19,958
-19,958
-50% -$361K ﹤0.01% 949
2026
Q1 		$801K Buy
+39,916
New +$933K 0.01% 593

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Clearstead Advisors's LYEL Position: Q2 2026 in Review

Clearstead Advisors reduced its Lyell Immunopharma (LYEL) stake by 50% in Q2 2026, selling an estimated $361K and leaving 19,958 shares worth $280K. The position accounts for ﹤0.01% of the portfolio, ranked #949.

Clearstead Advisors first reported a position in LYEL in Q1 2026 and has held it in 2 quarters since. The position peaked at $801K in Q1 2026. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Clearstead Advisors held 19,958 shares of Lyell Immunopharma worth $280K as of Q2 2026.
  • Clearstead Advisors sold 19,958 Lyell Immunopharma shares in Q2 2026, an estimated $361K.
  • Lyell Immunopharma made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #949 holding.
  • Clearstead Advisors first reported a position in Lyell Immunopharma in Q1 2026 and has held it in 2 quarters since.
  • Clearstead Advisors's Lyell Immunopharma position peaked at $801K in Q1 2026.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.